Exhibition Review | Chinese Peptide Company Biochemistry Attended the 17th China International Peptide Conference

The 17th China International Peptide Symposium was successfully concluded in Tianjin from June 14-16, 2023!) Peptide and drug. The conference will showcase new achievements and developments in peptides and related fields at home and abroad in recent years, enhance the communication and cooperation among scholars at home and abroad, promote the deep integration of industry, academia and research, and promote the research and industrial development of peptides in China and the world.

Chinese Peptide company is co-sponsored by famous scientists from home and abroad who have made outstanding achievements in the field of peptides, including the expert of synthetic insulin in China and Nobel Prize winner Merrifield. It has been held every two years since 1990, and has been held for sixteen consecutive years, becoming one of the most important and influential peptide conferences in the world.

Chinese Peptide company was invited to participate in the 2nd Peptide Drug Industry Innovation Forum, and there was a strong atmosphere of academic exchange, during which Chinese Peptide company exhibitors had a lively discussion with all the guests and industry colleagues, and introduced the latest research progress in the leading fields of peptide and nucleic acid CRDMO services.

Founded in 2001, Chinese peptide  company is a trusted global integrated peptide/nucleic acid CRDMO partner. The production base of the Chinese peptide company and the new base in the United States will simultaneously ensure the product delivery of global customers, and provide global customers with a long-term stable supply chain of peptide apis, so as to better respond to the growing customer demand.

The peptide nucleic acid business is led by national and provincial experts. Nucleic acid project covers an area of 15 acres, construction area of about 26,700 square meters, after the completion of the project will form a 10-story ground building and three-story podium of modern drug research and development and production base. Through complementary and collaborative cooperation with Chinese peptide  company, the Group will eventually build a global polypeptide/nucleic acid integrated whole industry chain platform, determined to help partners more compliant, safe and efficient development of patients in urgent need of drugs, and will also provide more comprehensive services for more pharmaceutical companies around the world.